ANDRIY B / Shutterstock.com

1 May 2025NewsAmericasLiz Hockley

Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit

Duo behind Comirnaty fails to convince Delaware judge to dismiss Alnylam patent claims on grounds of invalidity.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Moderna wins reprieve in COVID-19 vaccine dispute

3 October 2024 Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

More on this story

Moderna wins reprieve in COVID-19 vaccine dispute

3 October 2024 Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

More on this story

Moderna wins reprieve in COVID-19 vaccine dispute

3 October 2024 Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.

Pfizer, Moderna vow appeals after split vaccine ruling

4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on Moderna’s COVID pledge also handed down.

Biotechnology

Moderna prevails in COVID-19 vaccine row at EPO

21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations.

More features

Novartis tops Big Pharma in global trademark portfolios

PierFerd hires partner with medtech expertise

NanoString to pay 10x Genomics $68m in global settlement

Federal Circuit revives CRISPR feud citing PTAB errors

UPC issues first decision on second medical use

Mayer Brown welcomes patent litigator in Washington, DC

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025